Teladoc Health (NYSE:TDOC) Price Target Cut to $15.00

Teladoc Health (NYSE:TDOC) had its target price lowered by analysts at Wells Fargo & Company from $17.00 to $15.00 in a research note issued to investors on Monday, Benzinga reports. The brokerage currently has an “equal weight” rating on the health services provider’s stock. Wells Fargo & Company‘s price target points to a potential upside of 17.69% from the company’s current price.

A number of other analysts have also recently commented on TDOC. Leerink Partnrs reaffirmed a “market perform” rating on shares of Teladoc Health in a research report on Monday, February 26th. Needham & Company LLC reaffirmed a “hold” rating on shares of Teladoc Health in a report on Friday, April 26th. Truist Financial cut their price target on shares of Teladoc Health from $23.00 to $17.00 and set a “hold” rating on the stock in a report on Wednesday, March 6th. Oppenheimer reduced their price target on shares of Teladoc Health from $26.00 to $21.00 and set an “outperform” rating for the company in a research report on Friday, April 26th. Finally, Royal Bank of Canada dropped their price objective on shares of Teladoc Health from $25.00 to $18.00 and set an “outperform” rating on the stock in a report on Friday, April 26th. Twelve analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $18.73.

Teladoc Health Stock Down 4.8 %

Shares of TDOC stock opened at $12.75 on Monday. The company has a market cap of $2.16 billion, a price-to-earnings ratio of -9.04 and a beta of 0.94. The company has a debt-to-equity ratio of 0.66, a current ratio of 3.54 and a quick ratio of 3.47. The stock’s fifty day moving average price is $14.69 and its 200 day moving average price is $17.67. Teladoc Health has a 1-year low of $12.65 and a 1-year high of $30.41.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings results on Thursday, April 25th. The health services provider reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.02). Teladoc Health had a negative net margin of 8.90% and a negative return on equity of 10.11%. The company had revenue of $646.13 million for the quarter, compared to analyst estimates of $637.31 million. During the same quarter in the previous year, the company posted ($0.37) EPS. The company’s revenue for the quarter was up 2.7% compared to the same quarter last year. On average, research analysts expect that Teladoc Health will post -1.06 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CAO Richard J. Napolitano sold 3,765 shares of the company’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $14.52, for a total value of $54,667.80. Following the completion of the transaction, the chief accounting officer now owns 18,077 shares of the company’s stock, valued at approximately $262,478.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Teladoc Health news, CEO Jason N. Gorevic sold 53,755 shares of the stock in a transaction on Monday, March 4th. The shares were sold at an average price of $14.52, for a total transaction of $780,522.60. Following the transaction, the chief executive officer now directly owns 653,073 shares of the company’s stock, valued at $9,482,619.96. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CAO Richard J. Napolitano sold 3,765 shares of Teladoc Health stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $14.52, for a total transaction of $54,667.80. Following the completion of the sale, the chief accounting officer now owns 18,077 shares in the company, valued at approximately $262,478.04. The disclosure for this sale can be found here. Over the last quarter, insiders sold 135,441 shares of company stock worth $2,038,251. Company insiders own 0.95% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. ICA Group Wealth Management LLC acquired a new position in shares of Teladoc Health during the fourth quarter valued at approximately $28,000. Hexagon Capital Partners LLC raised its stake in Teladoc Health by 204.4% in the 4th quarter. Hexagon Capital Partners LLC now owns 1,586 shares of the health services provider’s stock valued at $34,000 after purchasing an additional 1,065 shares during the last quarter. RIA Advisory Group LLC acquired a new position in Teladoc Health in the 4th quarter valued at $36,000. GAMMA Investing LLC purchased a new position in Teladoc Health in the 4th quarter valued at $41,000. Finally, Principal Securities Inc. acquired a new stake in Teladoc Health during the 4th quarter worth $45,000. 76.82% of the stock is owned by hedge funds and other institutional investors.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.